Pearl Hires New CEO

Xconomy San Francisco — 

Pearl Therapeutics, the Redwood City, CA-based developer of treatments for lung diseases, has named Charles (Chuck) Bramlage as its new CEO. Bramlage was most recently the president of pharmaceutical products for Covidien (NYSE: COV). Pearl, which raised $69 million in venture capital in October, was previously led by Howard Rosen. I wrote a feature in December about how the company beat a blockbuster drug for chronic obstructive pulmonary disease in a head-to-head study of 118 patients.